|View printer-friendly version|
New Data Presented on ASLAN’s varlitinib at ESMO 2019
The investigator-initiated trial was conducted by Dr Matthew Chau Hsien Ng and supported by ASLAN and the
The MTD of varlitinib combined with mFOLFIRI was 300mg BID administered orally. The overall response rate was 13% and median PFS was 4.2 months. Durable responses were observed in a biliary tract cancer patient (one prior line of chemotherapy) and a HER2 positive ovarian clear cell carcinoma patient (five prior lines of chemotherapy), maintained at 7.5 and 6.1 months respectively. The most commonly occurring adverse events were fatigue, oral mucositis, anorexia and grade 1/2 diarrhoea, with 0% grade 3/4 diarrhoea. As at
The abstract can be accessed on ASLAN’s website via this link.
Media and IR contacts
About varlitinib (ASLAN001)
Varlitinib (ASLAN001) is a highly potent, oral, reversible, small molecule pan-HER inhibitor that targets the human epidermal growth factor receptors HER1, HER2 and HER4. These receptors can be mutated or overexpressed in many tumours, which can cause excessive proliferative activity and uncontrolled growth. Therefore, by inhibiting the activation of the HER receptors, varlitinib could inhibit proliferation and control tumour growth. Varlitinib has been granted orphan drug designation in
Forward looking statements
This release contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of
All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.
Source: ASLAN PHARMACEUTICALS LIMITED